Azithromycin Versus Doxycycline on Restistin Level in Periodontitis Patients With Type 2 Diabetes

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

March 30, 2023

Study Completion Date

March 30, 2023

Conditions
Periodontal DiseasesType 2 Diabetes
Interventions
DRUG

Group I

First group are chronic periodontitis patients with diabetes mellitus type II who received scaling and root planning.

DRUG

Group II

Second group will receive 250 mg of azithromycin per day for a period of 5 days, after an initial dose of 500 mg one hour before NSPT.

DRUG

Group III

"Third group are Type 2 DM patients who received doxycycline 20mg twice/day.~Gingival crevicular fluid will be collected at 0, 1, and 3 months to assess Serum Resistin using a human Resistin enzyme-linked immunosorbent assay Kit following the manufacturer's protocol."

Trial Locations (1)

Unknown

King Abdulaziz University, Jeddah

All Listed Sponsors
lead

King Abdulaziz University

OTHER